LOGIN  |  REGISTER
Viking Therapeutics

Elevance Health Appoints Nathan Rich Vice President, Investor Relations

November 04, 2024 | Last Trade: US$365.96 0.52 -0.14

INDIANAPOLIS / Nov 04, 2024 / Business Wire / Elevance Health (NYSE: ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company’s growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company’s executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health’s Government Health Benefits business.

“Nate brings nearly two decades of experience spanning multiple sectors, including managed care, healthcare services, and consumer industries,” said Mark Kaye. “His diverse expertise, coupled with his analytical acumen will be instrumental in driving our strategy forward as we continue to evolve as a lifetime trusted health partner.”

Prior to joining Elevance Health, Mr. Rich served as Vice President in Global Investment Research at Goldman Sachs. He also held roles of increasing responsibility at Citi as a sell-side research analyst.

Mr. Rich holds a Bachelor of Science degree, magna cum laude, from New York University’s Leonard N. Stern School of Business.

About Elevance Health

Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve approximately 113 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB